🚀 go-pugleaf

Antibody cancer drugs in development – Anticorps en développement
comme thérapie anticancéreuse

Cancer Blog – Marc Lacroix – Blogue du Cancer

http://marclacroixcancerblog.blogspot.com/2011/09/antibody-cancer-drugs-in-development.html


Edrecolomab, Capromab Pendetide (111In), Votumumab Tc (99Tc),
Panitumumab, Satumomab pendetide (111In), Alemtuzumab, Gemtuzumab
ozogamicin Ofatumumab, Rituximab, Ibritumomab tiuxetan (111In 90Y),
Cetuximab, Igovomab (125I), Trastuzumab, Brentuximab Vedotin,
Etanercept, Alefacept, Catumaxomab, Tositumomab, Arcitumomab (99Tc),
Nofetumomab merpentan (99Tc), Tositumomab (I131), Abagovomab,
Epratuzumab (90Y), Ganitumab, Aflibercept, Mitumomab, Siltuximab,
Figitumumab, Obinutuzumab, Zalutumumab, Necitumumab, Bectumomab,
Oregovomab, Farletuzumab, Inotuzumab ozogamicin, Pertuzumab,
Pemtumomab, Lintuzumab, Detumomab, Nimotuzumab, Girentuximab,
Anatumomab mafenatox, Naptumomab estafenatox, Rilotumumab,
Conatumumab, Bavituximab, Intetumumab, Glembatumumab vedotin,
Tucotuzumab celmoleukin, Matuzumab, Tacatuzumab tetraxetan (90Y),
Mapatumumab, Labetuzumab (90Y), Olaratumab, Cixutumumab, Cantuzumab
ravtansine, Lorvotuzumab Mertansine, Veltuzumab, Clivatuzumab
tetraxetan (90Y), Milatuzumab, Iratumumab, Blinatumomab, Dalotuzumab,
Amatuximab, Adecatumumab, Drozitumab, Cantuzumab mertansine,
Robatumumab, Ficlatuzumab, Dacetuzumab, Tenatumomab, Tigatuzumab,
Ertumaxomab, Sontuzumab, Bivatuzumab mertansine, Moxetumomab
pasudotox, Lexatumumab, Lucatumumab, Flanvotumab, Narnatumab,
Altumomab pentetate (111In), Ensituximab, Elotuzumab, Enavatuzumab,
Trastuzumab Emtansine, Teprotumumab, Oportuzumab monatox, Citatuzumab
bogatox, Racotumomab, Cetuximab (Zr89), Daratumumab, Epitumomab,
Epitumomab cituxetan, Ibritumomab Tiuxetan (90Y), Minretumomab,
Nacolomab tafenatox, Pintumomab (99Tc), Pritumumab, Sibrotuzumab,
Taplitumomab paptox, Onartuzumab, Indatuximab ravtansine